Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Rhythm Biosciences Ltd, a company focused on early cancer detection technologies, has announced Dr. David Atkins as its new CEO. Dr. Atkins brings extensive global healthcare leadership experience, with a background in R&D, product development, and commercialization in various life sciences and healthcare disciplines. His appointment is expected to propel the company’s growth and enhance its cancer diagnostic product pipeline, with a view to making a global impact.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.
